Loading...

Akumin

TSX:AKU
Snowflake Description

Undervalued with high growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
AKU
TSX
CA$344M
Market Cap
  1. Home
  2. CA
  3. Healthcare
Company description

Akumin Inc. provides outpatient diagnostic imaging services in the United States. The last earnings update was 40 days ago. More info.


Add to Portfolio Compare Print
AKU Share Price and Events
7 Day Returns
5.3%
TSX:AKU
-0.5%
CA Healthcare
1.2%
CA Market
1 Year Returns
-
TSX:AKU
18.2%
CA Healthcare
-2.6%
CA Market
AKU Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Akumin (AKU) 5.3% 5.3% 13.6% - - -
CA Healthcare -0.5% -2.3% -1.1% 18.2% -4.2% 28.1%
CA Market 1.2% 1.3% 1% -2.6% 12.8% 2.2%
1 Year Return vs Industry and Market
  • No trading data on AKU.
  • No trading data on AKU.
Price Volatility
Industry
5yr Volatility vs Market

Value

 Is Akumin undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Akumin to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Akumin.

TSX:AKU Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 3 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 8.1%
Perpetual Growth Rate 10-Year CA Government Bond Rate 1.9%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for TSX:AKU
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year CA Govt Bond Rate 1.9%
Equity Risk Premium S&P Global 6%
Healthcare Unlevered Beta Simply Wall St/ S&P Global 0.64
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.641 (1 + (1- 26.5%) (86.93%))
1.033
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.03
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 1.95% + (1.033 * 5.96%)
8.11%

Discounted Cash Flow Calculation for TSX:AKU using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Akumin is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

TSX:AKU DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 8.11%)
2019 7.60 Analyst x1 7.03
2020 16.10 Analyst x1 13.78
2021 24.26 Est @ 50.69% 19.20
2022 33.01 Est @ 36.07% 24.17
2023 41.54 Est @ 25.83% 28.13
2024 49.29 Est @ 18.67% 30.88
2025 56.02 Est @ 13.65% 32.46
2026 61.70 Est @ 10.14% 33.08
2027 66.44 Est @ 7.68% 32.95
2028 70.40 Est @ 5.96% 32.29
Present value of next 10 years cash flows $253.97
TSX:AKU DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= $70.40 × (1 + 1.95%) ÷ (8.11% – 1.95%)
$1,165.36
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $1,165.36 ÷ (1 + 8.11%)10
$534.52
TSX:AKU Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $253.97 + $534.52
$788.49
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $788.49 / 68.83
$11.46
TSX:AKU Discount to Share Price
Calculation Result
Exchange Rate USD/CAD
(Reporting currency to currency of TSX:AKU)
1.321
Value per Share
(CAD)
= Value per Share in USD x Exchange Rate (USD/CAD)
= $11.46 x 1.321
CA$15.14
Value per share (CAD) From above. CA$15.14
Current discount Discount to share price of CA$5.00
= -1 x (CA$5.00 - CA$15.14) / CA$15.14
67%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Akumin is available for.
Intrinsic value
>50%
Share price is CA$5 vs Future cash flow value of CA$15.14
Current Discount Checks
For Akumin to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Akumin's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Akumin's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Akumin's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Akumin's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
TSX:AKU PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-03-31) in USD $0.10
TSX:AKU Share Price ** TSX (2019-06-21) in CAD CA$5
TSX:AKU Share Price converted to USD reporting currency Exchange rate (CAD/ USD) 0.757 $3.78
Canada Healthcare Industry PE Ratio Median Figure of 7 Publicly-Listed Healthcare Companies 47.26x
Canada Market PE Ratio Median Figure of 542 Publicly-Listed Companies 15.1x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Akumin.

TSX:AKU PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= TSX:AKU Share Price ÷ EPS (both in USD)

= 3.78 ÷ 0.10

38.38x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Akumin is good value based on earnings compared to the CA Healthcare industry average.
  • Akumin is overvalued based on earnings compared to the Canada market.
Price based on expected Growth
Does Akumin's expected growth come at a high price?
Raw Data
TSX:AKU PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 38.38x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts
95.1%per year
North America Healthcare Industry PEG Ratio Median Figure of 47 Publicly-Listed Healthcare Companies 1.67x
Canada Market PEG Ratio Median Figure of 248 Publicly-Listed Companies 1.18x

*Line of best fit is calculated by linear regression .

TSX:AKU PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 38.38x ÷ 95.1%

0.4x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Akumin is good value based on expected growth next year.
Price based on value of assets
What value do investors place on Akumin's assets?
Raw Data
TSX:AKU PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-03-31) in USD $1.72
TSX:AKU Share Price * TSX (2019-06-21) in CAD CA$5
TSX:AKU Share Price converted to USD reporting currency Exchange rate (CAD/ USD) 0.757 $3.78
Canada Healthcare Industry PB Ratio Median Figure of 23 Publicly-Listed Healthcare Companies 2.35x
Canada Market PB Ratio Median Figure of 2,425 Publicly-Listed Companies 1.43x
TSX:AKU PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= TSX:AKU Share Price ÷ Book Value per Share (both in USD)

= 3.78 ÷ 1.72

2.2x

* Primary Listing of Akumin.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Akumin is good value based on assets compared to the CA Healthcare industry average.
X
Value checks
We assess Akumin's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Healthcare industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Healthcare industry average (and greater than 0)? (1 check)
  5. Akumin has a total score of 5/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Akumin expected to perform in the next 1 to 3 years based on estimates from 3 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
95.1%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Akumin expected to grow at an attractive rate?
  • Akumin's earnings growth is expected to exceed the low risk savings rate of 1.9%.
Growth vs Market Checks
  • Akumin's earnings growth is expected to exceed the Canada market average.
  • Akumin's revenue growth is expected to exceed the Canada market average.
Annual Growth Rates Comparison
Raw Data
TSX:AKU Future Growth Rates Data Sources
Data Point Source Value (per year)
TSX:AKU Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts 95.1%
TSX:AKU Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 3 Analysts 30.5%
Canada Healthcare Industry Earnings Growth Rate Market Cap Weighted Average 53.7%
Canada Healthcare Industry Revenue Growth Rate Market Cap Weighted Average 16%
Canada Market Earnings Growth Rate Market Cap Weighted Average 14.9%
Canada Market Revenue Growth Rate Market Cap Weighted Average 5.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
TSX:AKU Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
TSX:AKU Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2020-12-31 299 24 3
2019-12-31 234 4 3
TSX:AKU Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-03-31 169 9 6
2018-12-31 155 6 5
2018-09-30 149 4 5
2018-06-30 134 2 -5
2018-03-31 109 5 -6
2017-12-31 90 5 -8
2017-06-30 62 2 -4
2016-09-30 46 3 -2

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Akumin's earnings are expected to grow significantly at over 20% yearly.
  • Akumin's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
TSX:AKU Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below

All data from Akumin Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

TSX:AKU Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2020-12-31 0.36 0.36 0.36 1.00
2019-12-31 0.06 0.06 0.06 1.00
TSX:AKU Past Financials Data
Date (Data in USD Millions) EPS *
2019-03-31 0.10
2018-12-31 0.09
2018-09-30 0.11
2018-06-30 -0.11
2018-03-31 -0.15
2017-12-31 -0.26
2017-06-30 -0.15
2016-09-30 -0.09

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Akumin will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Akumin's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Canada market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Canada market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Akumin has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Akumin performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Akumin's growth in the last year to its industry (Healthcare).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Akumin has delivered over 20% year on year earnings growth in the past 5 years.
  • Akumin has become profitable in the last year making the earnings growth rate difficult to compare to the 5-year average.
  • Akumin has become profitable in the last year making it difficult to compare the CA Healthcare industry average.
Earnings and Revenue History
Akumin's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Akumin Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

TSX:AKU Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-03-31 168.91 6.01 58.23
2018-12-31 154.78 5.00 57.18
2018-09-30 149.27 5.37 57.67
2018-06-30 134.24 -4.81 55.13
2018-03-31 109.35 -5.74 42.74
2017-12-31 90.25 -8.16 36.07
2017-06-30 62.44 -3.88 27.76
2016-09-30 46.40 -1.99 20.06
2015-09-30 35.04 -2.73 16.59

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Akumin has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • Akumin used its assets more efficiently than the CA Healthcare industry average last year based on Return on Assets.
  • Akumin has become profitable over the past 3 years. This is considered to be a significant improvement in its use of capital (Return on Capital Employed).
X
Past performance checks
We assess Akumin's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Healthcare industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Akumin has a total score of 3/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Akumin's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Akumin's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Akumin is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Akumin's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of Akumin's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is not covered by short term assets, assets are 0.5x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Akumin Company Filings, last reported 2 months ago.

TSX:AKU Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-03-31 110.08 113.36 18.90
2018-12-31 106.40 113.33 19.33
2018-09-30 103.04 101.23 20.37
2018-06-30 101.07 73.45 19.81
2018-03-31 82.74 73.37 9.88
2017-12-31 80.41 73.17 12.15
2017-06-30 16.47 36.26 6.22
2016-09-30 7.47 33.09 7.25
2015-09-30 4.13 27.16 3.01
  • Akumin's level of debt (106.6%) compared to net worth is high (greater than 40%).
  • Unable to establish if Akumin's debt level has increased without past 5-year debt data.
  • Debt is not well covered by operating cash flow (7.7%, less than 20% of total debt).
  • Interest payments on debt are not well covered by earnings (EBIT is 2.6x annual interest expense, ideally 3x coverage).
X
Financial health checks
We assess Akumin's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Akumin has a total score of 1/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Akumin's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Akumin dividends.
If you bought CA$2,000 of Akumin shares you are expected to receive CA$0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Akumin's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Akumin's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
TSX:AKU Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
North America Healthcare Industry Average Dividend Yield Market Cap Weighted Average of 25 Stocks 1.6%
Canada Market Average Dividend Yield Market Cap Weighted Average of 335 Stocks 3.5%
Canada Minimum Threshold Dividend Yield 10th Percentile 1.1%
Canada Bottom 25% Dividend Yield 25th Percentile 2.1%
Canada Top 25% Dividend Yield 75th Percentile 5.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

TSX:AKU Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Akumin has not reported any payouts.
  • Unable to verify if Akumin's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Akumin's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Akumin has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Akumin's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Akumin afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Akumin has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Akumin's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Riadh Zine Zine-El-Abidine
COMPENSATION $2,444,013
AGE 46
CEO Bio

Mr. Riadh Zine-El-Abidine also known as Riadh Zine, serves as Chief Executive Officer and President at Akumin Inc. Mr. Zine serves as President and Chief Executive Officer of Elite Imaging Inc. Mr. Zine is a Principal and Executive Chairman at Roadmap Capital Inc. He co-founded Roadmap Capital Inc. in August 2013. He has more than 15 years of experience executing public or private equity and debt financings, as well as mergers and acquisitions for a wide range of companies in the consumer, retail, healthcare, transportation and industrials sectors. Mr. Zine served as a Managing Director of Global Investment Banking at RBC Capital Markets, where he was responsible for providing strategic and financial advice to many of the largest corporations, entrepreneurs and private equity firms. Prior to joining RBC Capital Markets, he was employed at Royal Bank of Canada on a number of strategic projects, including the merger between Royal Bank of Canada and Bank of Montreal. He worked at a leading Canadian bank on a number of strategic projects. Prior to this, he worked at Royal Bank of Canada on a number of strategic projects. He has been Director at Akumin Inc since August 12, 2015. He served as a Director of Kure Technologies, Inc., (alternate name Unique Broadband Systems Inc.) since May 4, 2015 until February 28, 2017. Mr. Zine holds a M.Sc. in Financial Engineering from École des Hautes Études Commerciales, University of Montréal.

CEO Compensation
  • Riadh Zine's compensation has been consistent with company performance over the past year, both up more than 20%.
  • Riadh Zine's remuneration is higher than average for companies of similar size in Canada.
Management Team Tenure

Average tenure of the Akumin management team in years:

3.8
Average Tenure
  • The tenure for the Akumin management team is about average.
Management Team

Riadh Zine Zine-El-Abidine

TITLE
President
COMPENSATION
$2M
AGE
46

Mohammad Saleem

TITLE
CFO & Corporate Secretary
COMPENSATION
$705K
TENURE
3.8 yrs

Rohit Navani

TITLE
Executive VP & COO
COMPENSATION
$1M
TENURE
4.7 yrs

Amy Adams

TITLE
Senior Vice President
COMPENSATION
$795K

Laura Kassa

TITLE
Senior Vice President
COMPENSATION
$989K
TENURE
2.4 yrs

Matt Cameron

TITLE
Senior VP & General Counsel

Darren Speed

TITLE
Chief Compliance Officer

Karen Moore

TITLE
Vice President of Human Resources

Adam Fabian

TITLE
Corporate Controller

Christopher Fitzgerald

TITLE
Chief Revenue Officer of Akumin Corp
Board of Directors Tenure

Average tenure and age of the Akumin board of directors in years:

2.3
Average Tenure
58
Average Age
  • The average tenure for the Akumin board of directors is less than 3 years, this suggests a new board.
Board of Directors

Stan Dunford

TITLE
Chairman
COMPENSATION
$169K
AGE
68

Riadh Zine Zine-El-Abidine

TITLE
President
COMPENSATION
$2M
AGE
46
TENURE
3.8 yrs

Tom Davies

TITLE
Independent Director
COMPENSATION
$185K
AGE
59
TENURE
2.3 yrs

Murray Lee

TITLE
Lead Director
COMPENSATION
$195K
AGE
58

James Webb

TITLE
Independent Director
COMPENSATION
$178K
AGE
58
TENURE
1.8 yrs
Who owns this company?
Recent Insider Trading
  • Akumin individual insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (CA$) Value (CA$)
21. Jun 19 Sell Michael Meredith Individual 20. Jun 19 20. Jun 19 -3,367 CA$3.65 CA$-12,290
14. Jun 19 Sell Michael Luckey Individual 11. Jun 19 11. Jun 19 -6,635 CA$3.68 CA$-24,231
14. Jun 19 Sell Amy Adams Individual 12. Jun 19 12. Jun 19 -5,000 CA$3.75 CA$-18,750
03. Jun 19 Sell Marcus Quesenberry Individual 03. Jun 19 03. Jun 19 -6,735 CA$3.41 CA$-22,966
03. Jun 19 Sell Amy Adams Individual 30. May 19 30. May 19 -50,000 CA$3.35 CA$-167,500
X
Management checks
We assess Akumin's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Akumin has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Should Akumin Inc (TSE:AKU) Focus On Improving This Fundamental Metric?

While some investors are already well versed in financial metrics (hat tip), this article is for those who would like to learn about Return On Equity (ROE) and why it is important. … That means that for every CA$1 worth of shareholders' equity, it generated CA$0.089 in profit. … Return on Equity = Net Profit ÷ Shareholders' Equity

Simply Wall St -

Company Info

Description

Akumin Inc. provides outpatient diagnostic imaging services in the United States. As of December 31, 2018, the company operated 95 imaging centers located in Florida, Pennsylvania, Delaware, Texas, Illinois, and Kansas. Its centers provide physicians with imaging capabilities to facilitate the diagnosis and treatment of diseases and disorders, and reduce unnecessary invasive procedures. The company provides a range of medical imaging services, including magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, digital radiography, fluoroscopy, radiology, arthrography, biopsy, and other diagnostic or interventional radiology procedures; and online medical bill payment services. Akumin Inc. is headquartered in Toronto, Canada.

Details
Name: Akumin Inc.
AKU
Exchange: TSX
Founded:
CA$344,133,850
68,826,770
Website: http://www.akumin.com
Address: Akumin Inc.
151 Bloor Street West,
Suite 603,
Toronto,
Ontario, M5S 1S4,
Canada
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
TSX AKU Common Shares The Toronto Stock Exchange CA CAD 01. Dec 2017
OTCPK AKMN.F Common Shares Pink Sheets LLC US USD 01. Dec 2017
Number of employees
Current staff
Staff numbers
1,454
Akumin employees.
Industry
Health Care Services
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/06/24 00:56
End of day share price update: 2019/06/21 00:00
Last estimates confirmation: 2019/05/17
Last earnings filing: 2019/05/15
Last earnings reported: 2019/03/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.